Navigation Links
Review of probiotic trial research finds only Bifantis able to claim efficacy for IBS symptoms
Date:3/23/2009

CINCINNATI March 23, 2009 A review by researchers at Northwestern University (Chicago, IL.) and University of Michigan (Ann Arbor, MI) of the utility of probiotics in the treatment of Irritable Bowel Syndrome (IBS) found that Bifidobacterium infantis 35624 was the only probiotic strain out of 13 different individual strains or preparations reviewed to significantly improve symptoms of IBS, including abdominal pain, bloating and bowel movement difficulty. Bifidobacterium infantis 35624 is marketed as Bifantis® and can be found in a daily probiotic supplement by Procter & Gamble. The researchers reviewed 16 random-controlled-studies, evaluating the efficacy, safety and tolerability of probiotics in the treatment of IBS. With the exception of the Bifidobacterium infantis 35624 studies, researchers found the other trials did not use an appropriate study design and did not adequately report adverse events. The article was published on the American Journal of Gastroenterology website in advance of appearing in the publication's April 2009 issue1.

Irritable Bowel Syndrome affects one in five Americans and treatment options are limited. Darren. M Brenner, Division of Gastroenterology and Department of Internal Medicine, at Northwestern University and lead investigator of this study, hypothesized that alterations in gut microflora may contribute to the development of IBS symptoms, and believed these symptoms could be improved by probiotics. "Probiotics are gaining popularity for the treatment of multiple gastrointestinal disorders, including IBS," said Brenner, MD. "After assessment of the methodological and statistical designs of these studies, B. infantis 35624 was the only probiotic that showed repeated efficacy."

Clinical evidence and support for Bifantis continues to grow

Bifidobacterium infantis 35624, discovered in the early 1990s by microbiologists at Alimentary Health in Cork, Ireland in partnership with P&G, has been independently tested and evaluated in several clinical trials conducted with humans. This latest review provides continued clinical evidence of Bifantis efficacy in helping to manage a range of gastrointestinal issues including abdominal pain, bloating, constipation, diarrhea, gas and urgency. Bifantis efficacy data has been published or referenced in several medical journals, including the American Journal of Gastroenterology2 , Gastroenterology3 , New England Journal of Medicine4 , Public Library of Science (PLoS)5 and Nutrition in Clinical Practice6. Bifantis is found in the number one gastroenterologist recommended probiotic supplement in the United States7 .

Susan Abeln, Principal Scientist at Procter & Gamble said, "P&G has worked with Alimentary Health to study and develop a supplement with Bifantis because we firmly believe in the benefits of this strain for the millions of Americans struggling to manage digestive upsets each day. We're excited to make Bifantis available to consumers nationwide this spring."

Further credentialing the probiotic strain, P&G recently announced that Bifantis meets the probiotic guidelines established by The International Scientific Association for Probiotics and Prebiotics (ISAPP). These guidelines include five key criteria that consumers should consider when selecting a probiotic product - strain specificity, clinical proof, packaging, and the quality and quantity of probiotics in a product. Bifantis is proven to fully meet these guidelines, making it a good option for those who want to build and maintain a natural defense against abdominal discomfort and episodic digestive upsets such as constipation, diarrhea, urgency, gas and bloating.


'/>"/>

Contact: Chido Tsemunhu
Chido.Tsemunhu@mslworldwide.com
212-468-3681
Manning Selvage & Lee
Source:Eurekalert

Related biology news :

1. Stanford researchers publish review of US medical device regulation
2. Medicines derived from cannabis: a review of adverse events
3. Review article provides tools for the Rosaceae genomics community
4. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
5. Experts discuss applying systematic review to the field of nutrition
6. Biophysical Reviews makes debut in 2009
7. A re-review of peer review: Leading journal looks to end the review nightmare
8. Swedish university honors probiotics scientist
9. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
10. Vitamin E trials fatally flawed
11. Research team says extraterrestrial impact to blame for Ice Age extinctions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2016)... , March 17, 2016 ABI ... intelligence, forecasts the global biometrics market will reach ... impressive 118% increase from 2015. Consumer electronics, particularly ... embedded fingerprint sensors anticipated to reach two billion ... Dimitrios Pavlakis , Research Analyst at ...
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
(Date:3/11/2016)... --> --> ... Recognition Market by Technology (Pattern Recognition), by Component (Hardware, ... Type (On-Premises and Cloud), by Industry Vertical and by ... the global market is expected to grow from USD ... 2020, at a CAGR of 19.1%. , ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... May 25, 2016 , ... The American ... the Office of the National Coordinator for Health IT (ONC) outlining a measurement ... relevant data were available when and where it was needed. The organization of ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on the use ... W. Stellar has been named by the WEDI Board of Directors as WEDI’s president ... executive leader with more than 35 years of experience in healthcare, association management and ...
(Date:5/25/2016)... ... 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) ... company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar Ataxia ... , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is estimated ...
(Date:5/24/2016)... 2016   MedyMatch Technology Ltd ., the data analytics ... decision support tools in the emergency room, announced today that ... Advanced Technology Industries (IATI) BioMed Conference. The ... 15th National Life Sciences and Technology Week, and is being ... in Tel Aviv, Israel . Gene ...
Breaking Biology Technology: